Compare SOLS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | JAZZ |
|---|---|---|
| Founded | 2025 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.4B |
| IPO Year | N/A | 2007 |
| Metric | SOLS | JAZZ |
|---|---|---|
| Price | $65.72 | $165.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $63.33 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | $3,812,000,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $3.21 | $6.00 |
| Revenue Next Year | $3.83 | $6.35 |
| P/E Ratio | $30.09 | ★ N/A |
| Revenue Growth | ★ 4.47 | 4.14 |
| 52 Week Low | $40.43 | $95.49 |
| 52 Week High | $64.31 | $182.99 |
| Indicator | SOLS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 79.13 | 47.44 |
| Support Level | $61.10 | $165.01 |
| Resistance Level | $64.31 | $171.70 |
| Average True Range (ATR) | 2.48 | 5.62 |
| MACD | 0.61 | -0.37 |
| Stochastic Oscillator | 98.40 | 54.34 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.